As global competitive pressure accelerates and regulatory oversight increases, life sciences companies today face an unprecedented need to proactively manage research and licensing due diligence, protect business assets and increase revenue. In fact, most life sciences companies today look at in- and out-licensing of their intellectual property as an essential component of their growth strategy.

For life science investors, conducting thorough due diligence on potential investments is critical, especially because many investors in the sector invest in pre-revenue companies that do not have sturdy financial positions from which to court investors.

ImmuneVax provides a risk-management and risk-mitigating solution for life sciences companies involved in a wide range of activities. Our services help you at every stage from initial fundraising to licensing intellectual property to launching an IPO.